Updates in Inflammation and Secondary CVD Prevention

PROGRAM DESCRIPTION During this activity, Brendan M. Everett, MD, and Ishwarlal Jialal, MD, PhD, will provide an overview of the role of inflammation in the pathogenesis of atherosclerosis and atherothrombotic ...

PROGRAM DESCRIPTION
During this activity, Brendan M. Everett, MD, and Ishwarlal Jialal, MD, PhD, will provide an overview of the role of inflammation in the pathogenesis of atherosclerosis and atherothrombotic events and residual inflammatory risks in patients with CVD. The expert faculty will focus on the role of biomarkers in assessing secondary CVD risk and review the most recent clinical trial data from the completed CANTOS study and the ongoing CIRT trial. The activity will conclude with an interactive patient case moderated by Christie M. Ballantyne, MD, to demonstrate a patient at risk for secondary CVD and how managing inflammation may potentially reduce that risk. Participants will also be given the opportunity to pose questions and interact with the expert faculty during this time to enhance their knowledge and clinical practice.

EDUCATIONAL OBJECTIVES
Upon completion of this activity, participants should be able to:Explain the role of inflammation in the underlying pathogenesis of the development and progression of atherosclerosisIdentify the role of inflammatory biomarkers in the assessment of secondary CVD riskReview the results from clinical trials for emerging non-statin therapies targeting inflammation for the secondary prevention of CVD

---

Write the first review

Resource tags